Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Abiad Visits the Karantina Warehouse and Public Hospital with a Delegation from the Republic of Korea and UNICEF

 
Following the announcement of new contribution from the Republic of Korea to ensure new-borns’ lifesaving care across selected governmental hospitals and the availability of essential paediatric acute medications in primary healthcare centres, the minister of public health held a joint field visit to the Karantina warehouse and hospital with Korean Ambassador to Lebanon and UNICEF Representative. 

The new funding will ensure the access of vulnerable populations to essential medications at primary healthcare centres and intensive lifesaving care services in public hospitals to avoid any supply rupture and allow timely access to acute treatments for children and mothers.  

The Minister of Public Health, Dr. Firass Abiad, indicated that "this donation will contribute to supporting the most vulnerable". He pointed out that "this is not the first time that the Republic of Korea  and UNICEF have stood by Lebanon.  through cooperation with partners, the Ministry of Public Health, in light of the difficult economic and political circumstances in Lebanon and the fact that Lebanon is hosting large numbers of displaced people, is trying to fulfill its duties towards everyone by providing health services and medicine in Primary health care centers".

Ambassador of the Republic of Korea in Lebanon, Mr.  Il Park said: “Korea recognizes the importance of providing essential healthcare services to the most vulnerable members of society, particularly children and newborns. We firmly believe that every child deserves the right to receive proper medical attention and care, regardless of their circumstances.”

The procured acute medications includes antibiotics, and anti-inflammatories allow to fill the gap in the acute medication supply induced by high demand for care from the most vulnerable children in Lebanon. Supporting vulnerable families to cover the out of pocket payment for their infants and children intensive care services helps eliminate the financial barrier to accessing lifesaving care. 

Edouard Beigbeder, UNICEF Representative in Lebanon, emphasized the organization's dedication to bridging vital healthcare access disparities and maintaining life-saving assistance for mothers and children in Lebanon. “Thanks to the ongoing generous support from the Republic of Korea, we can broaden our initiatives to encompass more vulnerable areas and additional hospitals, with a particular focus on enhancing support in Baalbek and Akkar."
    5
ATC Name B/G Ingredients Dosage Form Price
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 2.5g/50ml Injectable solution 19,540,934 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 5g/100ml Injectable solution 37,672,334 L.L
J06BA02 OCTAGAM 10% BioHuman Human normal immunoglobulin G - 10% 5g/50ml Injectable solution 37,672,334 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 10g/200ml Injectable solution 71,676,672 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft L.L
L01EX09 OFEV B Nintedanib - 100mg 100mg Capsule, soft 100,972,184 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft 201,946,695 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution 117,224,380 L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution 51,234,726 L.L
L01XA03 OXALIPLATIN HOSPIRA G Oxaliplatin - 100mg/20ml 5mg/ml Injectable concentrated solution 8,471,583 L.L
L01XA03 OXALIPLATIN MEDAC G Oxaliplatin - 100mg 100mg Injectable powder for solution 7,841,801 L.L
L01XA03 OXALIPLATINE VIATRIS 5MG/ML G Oxaliplatin - 100mg 100mg Injectable powder for solution 6,932,000 L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution 6,199,145 L.L
L01XA03 OXALTIE G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution 5,915,595 L.L
L01XA03 OXALIPLATIN EBEWE G Oxaliplatin - 50mg/10ml 50mg/10ml Injectable concentrated solution 3,405,297 L.L
L01XA03 OXALIPLATIN HOSPIRA G Oxaliplatin - 50mg/10ml 5mg/ml Injectable concentrated solution 3,450,988 L.L
L01XA03 OXALIPLATIN MEDAC G Oxaliplatin - 50mg 50mg Injectable powder for solution 3,440,237 L.L
L01XA03 OXALIPLATINE VIATRIS 5MG/ML G Oxaliplatin - 50mg 50mg Injectable powder for solution 4,259,872 L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,957,797 L.L
L01XA03 OXALTIE G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,957,797 L.L
L01XA03 OXALTIE G Oxaliplatin - 50mg 50mg Injectable lyophilised powder 2,957,797 L.L
L01XX24 ONCASPAR B Pegaspargase - 750U/ml 750U/ml Injectable powder for solution 172,758,585 L.L
L01XX24 ONCASPAR B Pegaspargase - 750U/ml 750U/ml Injectable powder for solution L.L
L04AA32 OTEZLA B Apremilast - 4x10mg- 4x20mg- 19x30mg Tablet, film coated 34,751,325 L.L
L04AA32 OTEZLA B Apremilast - 30mg 30mg Tablet, film coated 49,829,454 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L04AA37 OLUMIANT B Baricitinib - 2mg 2mg Tablet, film coated 68,053,864 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025